Unknown

Dataset Information

0

Clinical utility of evolocumab in the management of hyperlipidemia: patient selection and follow-up.


ABSTRACT: Inhibition of PCSK9 is a novel therapeutic strategy aimed at reducing low-density-lipoprotein cholesterol (LDL-C) and cardiovascular risk. Evolocumab is a fully humanized monoclonal antibody that inhibits PCSK9, an enzyme that binds to LDL receptors and prevents them from recycling to the hepatocyte surface. Clinical trials have demonstrated 50%-70% reductions in LDL-C with evolocumab when used in combination with statin therapy. The recent FOURIER trial demonstrated that evolocumab further reduces cardiovascular events, but not mortality, in high-risk patients already receiving statin therapy. Furthermore, evolocumab did not affect neurocognitive function and was not associated with antidrug-antibody production in over 60,000 patient-years of drug exposure. Appropriate candidates for evolocumab primarily are individuals at high cardiovascular risk, including those with familial hypercholesterolemia and/or established cardiovascular disease, who are already on statin therapy. At this time, the use of evolocumab monotherapy seems appropriate only for individuals deemed statin-intolerant despite attempting several statins. Consideration must be given toward patient willingness to self-inject evolocumab and issues concerning third-party coverage, given the current costs of evolocumab.

SUBMITTER: Dixon DL 

PROVIDER: S-EPMC5513834 | biostudies-other | 2017

REPOSITORIES: biostudies-other

altmetric image

Publications

Clinical utility of evolocumab in the management of hyperlipidemia: patient selection and follow-up.

Dixon Dave L DL   Buckley Leo F LF   Trankle Cory R CR   Kadariya Dinesh D   Abbate Antonio A  

Drug design, development and therapy 20170711


Inhibition of PCSK9 is a novel therapeutic strategy aimed at reducing low-density-lipoprotein cholesterol (LDL-C) and cardiovascular risk. Evolocumab is a fully humanized monoclonal antibody that inhibits PCSK9, an enzyme that binds to LDL receptors and prevents them from recycling to the hepatocyte surface. Clinical trials have demonstrated 50%-70% reductions in LDL-C with evolocumab when used in combination with statin therapy. The recent FOURIER trial demonstrated that evolocumab further redu  ...[more]

Similar Datasets

| S-EPMC9762257 | biostudies-literature
2005-01-18 | GSE1907 | GEO
| PRJEB3227 | ENA
| S-EPMC7497299 | biostudies-literature
| S-EPMC7291114 | biostudies-literature
| S-EPMC7484757 | biostudies-literature
| S-EPMC5306419 | biostudies-literature
| S-EPMC4652674 | biostudies-literature
| S-EPMC4806952 | biostudies-literature
| PRJEB20076 | ENA